C3 Glomerulonephritis associated with Anti-complement Factor H Autoantibodies in an Adolescent Male: A Case Report

HyeSun Hyun, M.D.1,*
Hee Gyung Kang, M.D., Ph.D.2,4
UiJu Cho, M.D., Ph.D.3
Il-Soo Ha, M.D., Ph.D.2,4
Hae Il Cheong, M.D., Ph.D.2,4,*

1Department of Pediatrics, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, Korea; 2Department of Pediatrics, Seoul National University Children’s Hospital, Seoul, Korea; 3Department of Pathology, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, Korea; 4Research Coordination Center for Rare Diseases, Seoul National University Hospital, Seoul, Korea

*Both authors contributed equally to the work.

Corresponding author: Hae Il Cheong, M.D., Ph.D.
Department of Pediatrics Seoul National University Children’s Hospital 101 Daehak-Ro, Jongno-gu, Seoul 03080, Korea
Tel: +82-2-2072-2810
Fax: +82-2-2072-2810
E-mail: Cheonghi@snu.ac.kr

Corresponding author: HyeSun Hyun, MD
Department of Pediatrics St. Vincent’s Hospital, The Catholic University of Korea, Seoul, 93 Jungbu-daero, Paladal-gu, Suwon, gyeonggi-do 16247
Tel: +82-31-249-7320
Fax: +82-31-257-9111
E-mail: inchy@naver.com

Introduction

Dysregulation of the alternative pathway of the complement system causes various kidney diseases; C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS) represent such complement-driven glomerular diseases1).

C3G, a relatively new diagnostic category, is characterized by isolated or predominant glomerular C3 deposition1,2). C3G affects both children and adults who typically show persistent hematuria with or without proteinuria and progressive renal failure. C3G may present with a wide spectrum of clinical manifestations. Based on renal biopsy findings, C3G is categorized into dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). DDD,
formerly referred to as membranoproliferative glomerulonephritis (MPGN) type II, is characterized by dense osmophilic intramembranous glomerular deposits, and C3GN is characterized by predominantly C3 deposits in the mesangial, subendothelial, and subepithelial glomerular areas

Several inherited and acquired abnormalities cause C3G. Genetic causes include pathogenetic mutations in complement-related genes, such as C3, CFB, CFH, CFI, and CFHR 5, which encode C3, complement factor B (CFB), complement factor H (CFH), complement factor I, and CFH-related protein 5, respectively. Acquired abnormalities are associated with development of autoantibodies against complement proteins and complexes; for example, C3 nephritic factor (C3NeF) that targets C3 convertase, C5NeF that targets C5 convertase, anti-CFH autoantibodies, and anti-CFB autoantibodies

CFH is the main plasma regulatory protein of the alternative pathway of the complement system, and a significant percentage of patients with aHUS, particularly children develop anti-CFH autoantibodies, which were first implicated as contributors to aHUS in 2005. Anti-CFH autoantibodies mainly develop secondary to a homozygous deletion of CFHR1 and CFHR3 encoding CFHR1 and CFHR3, respectively. Anti-CFH autoantibodies also occur in a few patients with C3G. However, unlike patients with aHUS, those with C3G and anti-CFH autoantibodies do not show CFHR1 and CFHR3 deficiency.

Anti-CFH-associated C3G is rare; Durey et al. reported 23 cases, including 6 pediatric cases in 2016. We report a case of C3GN associated with anti-CFH autoantibodies and homozygous CFHR1/CFHR3 deletion together with a literature review.

**Case report**

A 16-year-old adolescent male without a family history of renal disease presented to a local hospital with a 1-month history of generalized edema. Asymptomatic microscopic hematuria was first detected at 7 years of age. At 10 years of age, he developed cervical lymphadenitis with fever; however, serum creatinine level was normal (0.6 mg/dL), and the C3 level was 31 mg/dL (normal range 80–150 mg/dL). His serum hemoglobin level was 12 g/dL, platelet count was 241×10^9/L. Urinalysis showed 4+ proteinuria and microscopic hematuria. His fever defervesced, and proteinuria decreased to 1+ with symptomatic treatment, on the second day of hospitalization. Following symptomatic improvement, he was discharged on the fourth day of admission and experienced no subjective symptoms post-discharge; however, low serum C3 levels and proteinuria with microscopic hematuria persisted over 3 years. Unfortunately, the patient was lost to follow-up for 4 years.

At 16 years of age, the patient noticed generalized edema with 3-kg weight gain over a month. His blood pressure was 120/80 mmHg, and body temperature was 36.8°C. He was 170 cm tall and weighed 58 kg. Laboratory test results showed white blood cells 9,580/µL, platelets 387×10^9/L, serum hemoglobin level 14 g/dL, serum proteins 3.9 g/dL, albumin 1.9 g/dL, creatinine 0.6 mg/dL, C3 was 17 mg/dL, and C4 was 22 mg/mL (normal range 17–40 mg/mL). Serum immunoglobulin (Ig) G, A, and M levels were normal. Urinalysis showed 4+ proteinuria, microscopic hematuria, and 24-hour urinary protein excretion of 3.7 g/day. Renal ultrasonography revealed increased renal parenchymal echogenicity bilaterally. Renal biopsy was performed (Fig. 1); light microscopy examination of the biopsy

![Kidney biopsy findings of the patient. Light microscopy examination (A) of the renal biopsy specimen revealed lobular accentuation of the glomerulus, mesangial matrix expansion, and focal tram track appearance of the glomerular capillary walls. Immunofluorescence microscopy (B) showed predominant deposition of C3 in the mesangium and peripheral capillary walls. Electron microscopy (C) revealed electron-dense deposits in subendothelial and mesangial areas.](image-url)
specimen revealed lobular accentuation of the glomeruli, mesangial matrix expansion, and a tram-track appearance of the glomerular capillary walls. The glomerular sclerosis were noted in 4 of the 30 glomeruli. Thrombus or fragmented red blood cells within glomeruli, in subendothelial areas, and in the mesangium and endothelial swelling or denudation were not seen. Immunofluorescence microscopy revealed C3 (4+) and IgM (1+) deposits in the mesangium and the capillary walls. Electron microscopy revealed subendothelial and mesangial electron-dense deposits. These histopathological findings were consistent with those observed in C3GN, and the patient received intravenous methylprednisolone, followed by oral prednisolone, mycophenolate, and an angiotensin-receptor blocker. Proteinuria persisted despite treatment; however, renal function remained stable throughout follow-up (Table 1).

Western blot analysis performed at 18 years of age revealed normal CFH levels with complete lack of plasma CFHR1 (Fig. 2). Multiplex ligation-dependent probe amplification assay using a commercial kit (SALSA MLPA Probenmix P236-A3 ARMD mix-1, MRC-Holland, Amsterdam, The Netherlands) confirmed homozygous CFHR1 and CFHR3 deletion. Plasma anti-CFH IgG testing using a commercially available ELISA kit (CFH IgG ELISA kit, Abnova, Heidelberg, Germany) revealed a titer higher than that observed in healthy subjects. However, the titer was lower than that in patients with anti-CFH-associated aHUS, which may be attributed to decreased anti-CFH autoantibody production secondary to chronic immunosuppression (Table 2).

The patient was diagnosed with C3GN associated with anti-CFH autoantibodies and homozygous CFHR1/CFHR3 deletion.

Table 1. Serial laboratory findings of the patient

| Assay                  | Age of the patient (years) | 10* | 11 | 12 | 16* | 17 | 18 | 19 |
|------------------------|-----------------------------|-----|----|----|-----|----|----|----|
| Hemoglobin (g/dL)      |                             | 12  | n.a.| 13.6| 14  | 14.1| 15.8| 14.4|
| Platelet (x10^9/L)     |                             | 241 | n.a.| 260 | 387 | 179 | 343 | 328|
| Albumin (g/dL)         |                             | 3.2 | n.a.| 3.9 | 1.9 | 3.5 | 2.7 | 2.8|
| Creatinine (mg/dL)     |                             | 0.6 | 0.6 | 0.6 | 0.6 | 0.7 | 0.6 | 0.7|
| C3 (mg/dL)*            |                             | 31  | 11  | 12.4| 17  | 12  | 17  | n.a.|
| Urine protein          |                             | 4+  | 1+  | 2+  | 3+  | 4+  | 4+  | 4+  |
| Urine RBC (HPF)        |                             | many| 10–29| 10–29| many| many| 10–29| 10–29|
| Spot urine protein/creatinine (mg/mg) | n.a. | n.a. | 3.4 | 3   | 3.4 | 2.3 |

*When the patient had cervical lymphadenitis; †When the patient had glomerulonephritis; ‡Reference range 80–150 mg/dL. n.a., not available.

Table 2. Titers of plasma anti-CFH autoantibodies by ELISA

|                   | Arbitrary unit |
|-------------------|----------------|
| Healthy control 1 | -980           |
| Healthy control 2 | -291           |
| The patient       | 1,640          |
| Disease control 1*| 17,800         |
| Disease control 2*| 17,709         |

*Patients with atypical hemolytic uremic syndrome in association with anti-CFH autoantibodies and homozygous deletions of CFHR1 and CFHR3.
Discussion

MPGN was previously classified into types I, II, and III based on histopathological and ultrastructural findings. MPGN types I and II (also known as DDD) are characterized by subendothelial as well as mesangial deposits and highly osmophilic electron-dense intramembranous deposits, respectively. MPGN type III is typically associated with both subendothelial and subepithelial deposits. A consensus meeting of renal pathologists and nephrologists held in 2015 to establish an etiology/pathogenesis-based system for classification and diagnosis of GN, recommended a new classification of GN into the following pathogenetic types: immune-complex GN, pauci-immune GN, antiglomerular basement membrane GN, monoclonal immunoglobulin GN, and C3G. Accordingly, MPGN is reclassified into immune complex-mediated MPGN (characterized by immunoglobulin and C3 deposition associated with abnormal activation of the classical complement pathway), and complement-mediated MPGN (defined as C3G characterized by isolated or predominant C3 deposition associated with abnormal activation of the alternative complement pathway). C3G includes DDD and C3GN.

Dysregulation of the alternative complement pathway may occur secondary to genetic mutations in complement-related genes or as an acquired abnormality. Development of autoantibodies, including C3NeF, C5NeF, anti-CFH autoantibodies, and anti-CFB autoantibodies constitutes the most frequent acquired abnormality. C3NeF, the first described and most commonly observed autoantibody, primarily occurs in patients with DDD but less frequently in patients with C3GN. Anti-CFH autoantibodies, first described in patients with aHUS in 2005, occur in a significant percentage of children with aHUS but in only a few patients with C3G. Two large cohort studies of C3G, the Columbia University and the Mayo Clinic cohort have described these autoantibodies.

In the Columbia University cohort study, the prevalence of C3NeF and anti-CFH autoantibodies was 31.0% and 7.1%, respectively among 42 patients with C3GN. Similarly, the Mayo Clinic cohort study reported that the prevalence of C3NeF and other autoantibodies (C5NeF, C4NeF, anti-CFH autoantibodies, and anti-CFB autoantibodies) was 37.8% and 16.7%, respectively among patients with C3GN who showed negative results for monoclonal gammopathy (which commonly causes C3G in adults). The Columbia University cohort included children (31.5%) and adults, whereas the Mayo Clinic cohort included mainly adults.

CFH, the key regulator of the alternative pathway of the complement system, controls complement levels in both the fluid phase and on cell surfaces. The C-terminal region of CFH is associated with surface recognition, whereas the N-terminal region promotes cofactor and decay-accelerating activity. C3G is associated with defective fluid phase C3 regulation with genetic mutations in the N-terminal region of CFH, and autoantibodies show N-terminal specificity. In contrast, aHUS is associated with uncontrolled complement activation on endothelial cells, and mutations and autoantibodies affect the C-terminal region of CFH. Moreover, anti-CFH autoantibodies in patients with aHUS are primarily associated with homozygous CFHR1 and CFHR3 deletion, although the mechanism by which CFHR1/CFHR3 deficiency promotes anti-CFH antibody production is unknown.

In contrast to patients with aHUS, those with C3G and anti-CFH autoantibodies do not show CFHR1 and CFHR3 deficiencies. Our case report is the first to describe C3GN associated with anti-CFH autoantibodies and homozygous CFHR1/CFHR3 deletion. In this patient, the CFHR1/CFHR3 deletion led to develop anti-CFH antibody that has different properties from those develop in patients with aHUS. Further studies are needed on the association of anti-CFH autoantibodies and CFHR1/CFHR3 deletion in C3G patients.

A French study reported that the mean anti-CFH autoantibody titer in patients with C3G was comparable with that in patients with aHUS. Despite similar titers, the avidity of anti-CFH autoantibodies in C3G patients was lower than those of aHUS patients. Lower avidity of antibody binding to CFH in patients with anti-CFH-associated C3G than in patients with anti-CFH-associated aHUS may contribute to lower immune-complex generation rates. In our patient, anti-CFH autoantibodies were not measured during the acute stage of the illness but only 2 years after disease onset. Therefore, the relatively lower titer of anti-CFH autoantibodies in our patient may reflect decreased anti-CFH antibody production secondary to steroid and
Although C3G can present at all ages, it most commonly occurs during late adolescence and early adulthood. Notably, DDD manifests earlier than C3GN, and C3G shows no sex predilection. Renal manifestations of C3GN include hematuria, hypertension, and commonly nephrotic-range proteinuria. Low C3 levels are observed in approximately 66% of patients, and kidney biopsy is essential for definitive diagnosis. Progression to kidney failure is common, with high recurrence rates after renal transplantation. Our patient had persistent low C3 level since age 10. Our speculation is that the patient already had C3 dysregulation at the age of 10 years when low serum C3 level was first detected. The patient probably had C3 dysregulation before age 10, and cervical lymphadenitis at the age of 10 exacerbated it. It is well-known that nonspecific infections can induce complement activation.

Current treatment recommendations for C3G (based on data from case series and observational studies), include administration of corticosteroids, antiproliferative drugs (cyclophosphamide, mycophenolate mofetil), and monoclonal antibodies (rituximab), which inhibit factors that trigger complement pathway activation. Although eculizumab therapy is deemed useful, few reports have discussed its efficacy in patients with C3G. Owing to limited research in this field, information regarding optimal treatment and prognosis of patients with anti-CFH-mediated C3G is unavailable. In addition to corticosteroids and immunosuppressants, plasma exchanges and B-cell inhibitor administration are considered feasible therapeutic strategies for C3G associated with autoantibodies, including anti-CFH autoantibodies and C3Nef.

In conclusion, we report the first case of C3GN associated with anti-CFH autoantibodies and homozygous CFCR1/CFCR3 deletion in an adolescent Korean male. This rare case highlights the importance of genetic testing and complement factor assay in patients with persistently low C3 levels.

Acknowledgement

This research was supported by a grant of the Korea Health Technology Research & Development Projectthrough the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C0013).

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

ORCID iDs

HyeSun Hyun http://orcid.org/0000-0001-8525-1471
Hee Gyung Kang http://orcid.org/0000-0001-8323-5320
UiJu Cho http://orcid.org/0000-0002-6229-8418
Il-Soo Ha http://orcid.org/0000-0001-5428-6209
Hae Il Cheong http://orcid.org/0000-0001-7556-1265

References

1. Caravaca-Fontán F, Lucientes L, Cavero T, Praga M. Update on C3 glomerulopathy: a complement-mediated disease. Nephron 2020;144:272-80.
2. Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol 2015;11:14-22.
3. Ahmad SB, Bomback AS. C3 glomerulopathy: pathogenesis and treatment. Adv Chronic Kidney Dis 2020;27:104-10.
4. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:555-3.
5. Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, André JL, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010; 21:2180-7.
6. Lee BH, Kwak SH, Shin JI, Lee SH, Choi HJ, Kang HG, et al. Atypical hemolytic uremic syndrome associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009;66:336-40.
7. Lee JM, Park YS, Lee JH, Park SJ, Shin JJ, Park YH, et al. Atypical hemolytic uremic syndrome: Korean pediatric series. Pediatr Int 2015;57:431-8.
8. Blanc C, Togarsimalemath SK, Chauvet S, Le Quintrec M, Moulin B, Buchler M, et al. Anti-factor H autoantibodies in C3 glomerulopathies and atypical hemolytic uremic syndrome: one target, two diseases. J Immunol 2015;194:5129-38.
9. Durey MA, Sinha A, Togarsimalemath SK, Bagga A. Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 2016;12:563-78.

10. Salvadori M, Rosso G. Reclassification of membranoproliferative glomerulonephritis: identification of a new GN: C3GN. World J Nephrol 2016;5:308-20.

11. Sethi S, Haas M, Markowitz GS, D’Agati VD, Rennke HG, Jennette JC, et al. Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. J Am Soc Nephrol 2016;27:1278-87.

12. Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012;82:454-64.

13. Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, et al. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 2018;93:977-85.

14. Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S. C3 glomerulopathy: ten years’ experience at Mayo Clinic. Mayo Clin Proc 2018;93:991-1008.

15. Riedl M, Thorner P, Licht C. C3 glomerulopathy. Pediatr Nephrol 2017;32:43-57.